Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements: early-phase trial registry
6 of 9 indexed High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 6 currently recruiting · #1,916 of 28,707 conditions by registered trial count
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements: 9 US clinical trials tracked, 6 recruiting.
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is University of Washington, running 2 of these trials.
Enrollment posture brief
Registry condition high-grade-b-cell-lymphoma-with-myc-and-bcl2-andor-bcl6-rearrangements
OPEN 6 | RECR 67% | LATE 0 | EARLY 9 | RANK #1916 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements lists 6 open slots (67% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements is recruiting above its size-band peers.
6 of 9 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements research.
University of Washington accounts for 2 of 9 trials (22.2%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 9 trials that report a genuine target (sentinel values excluded). 7 of those (77.8%) plan for fewer than 100 participants.
-
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements research is mostly interventional.
9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT01371630
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
SWOG Cancer Research Network
NCT05890352
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
University of Washington
NCT04231877
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
National Cancer Institute (NCI)
NCT07069699
Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma
Joseph Tuscano
NCT05600686
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
University of Washington
NCT07097363
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
National Cancer Institute (NCI)
NCT03038672
Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
David Bond, MD
NCT03749018
Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma
Northwestern University
NCT03742258
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements page
9 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Washington sponsors the most High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements trials on record, review their full trial history before evaluating a specific study. See University of Washington's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements condition card totals 9 registered trials; most-linked intervention Cyclophosphamide; top US site state Illinois. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.